Common Cholesterol Drug Cuts Heart Events by 30% in Seniors
A large clinical study involving nearly 10,000 individuals aged 70 and older found that atorvastatin, a common cholesterol-lowering drug, significantly reduced the risk of heart attacks, strokes, and other cardiovascular events. The research, known as the STAREE trial, included participants who did not have pre-existing heart disease, diabetes, or dementia.
The study, presented at the ESC Congress 2026 and published in the New England Journal of Medicine, randomly assigned participants to receive either 40 mg of atorvastatin daily or a placebo. After nearly six years of follow-up, the atorvastatin group experienced a relative reduction of approximately 30% in major cardiovascular events compared to the placebo group. These events included cardiovascular death, non-fatal heart attacks, strokes, and the need for procedures like angioplasty or bypass surgery.
While the drug proved effective in preventing cardiovascular incidents, it did not show a significant benefit in extending life free from dementia or persistent physical disability. The rates of death, dementia, or long-term disability were similar between the atorvastatin and placebo groups. Furthermore, the study noted a higher incidence of muscle-related issues, liver problems, and diabetes among those taking atorvastatin, which are particularly important considerations for older adults already managing multiple health conditions and medications.
Researchers emphasized that these findings do not constitute a recommendation for all individuals over 70 to start taking statins. The decision to prescribe statins should remain individualized, based on a comprehensive assessment of a patient's risk factors, including cholesterol levels, blood pressure, smoking status, existing conditions, and family history. The study provides valuable evidence for the primary prevention of cardiovascular events in older adults without known heart disease, adding crucial data to the ongoing discussion about statin use in this demographic.
In Israel, where statins are widely used, these new findings may inform discussions between doctors and patients regarding preventive treatment for older individuals who have not previously experienced a heart attack or stroke. The core message is that for appropriate older patients, cholesterol-lowering therapy can be a significant tool in preventing a first heart attack or stroke.
